- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic Leukemia
July 03, 2022
During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.
The Ideal Patient for Biomarker Testing in Anal Carcinoma
July 02, 2022
Cathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.
McKay Discusses Important Updates in Treatment, Management of Clear Cell RCC
July 02, 2022
During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed updates to key trials in advanced clear cell renal cell carcinoma.
Frontline Tislelizumab Plus Chemo Achieves 34% Reduction in Risk of Death in Advanced ESCC
July 01, 2022
In the RATIONALE 306 clinical trial, the combination of tislelizumab and chemotherapy achieved a 34% reduction in the risk of death in patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma with either high or low PD-L1 expression.
Considering Treatment for Patients with HCC and Autoimmune Disease
July 01, 2022
During a live virtual event, Daneng Li, MD, discussed the case of a 77-year-old woman with stage IV hepatocellular cancer and a Child-Pugh score of A. This is the first of 2 articles from this event.
Roundtable Discussion: Sabari Evaluates Immunotherapy, Targeted Therapy Options in ES-SCLC
July 01, 2022
During a case-based roundtable event, Joshua K. Sabari, MD, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer.
A Look Back at FDA News from June 2022
July 01, 2022
A look back at all of the FDA happenings of June 2022.
FDA Warns About Possible Increased Risk of Death and Side Effects With Duvelisib
July 01, 2022
Duvelisib shows possibility of increased risk of death and serious side effects vs other medicines in patients with leukemia and lymphoma.
FDA Grants Orphan Drug Designation to PT886 for Pancreatic Cancer
July 01, 2022
PT886 was granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
Factors Influencing Treatment Options for Stage 1B Grade 3 Endometrial Cancer
July 01, 2022
David Barrington, MD, discusses the key takeaways regarding the factors associated with variation of adjuvant treatments for patients with stage 1B, grade 3 endometrial cancer.
Reviewing Erlotinib/Binimetinib Combo in EGFR+ or KRAS+ NSCLC
June 30, 2022
Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.
Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma
June 30, 2022
In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.